Company intelligence / Profile preview
Solu Therapeutics
Boston, Massachusetts, USAsolutherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Solu Therapeutics has initiated a Phase 1 clinical trial for STX-0712, a CCR2-targeting CyTAC therapy, in patients with CMML and other hematologic malignancies.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Bifunctional small molecules linked to antibodies (CyTAC and TicTAC platforms)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
GSK (exclusive license for CyTAC platform)Eli Lilly & CompanyBiovision VenturesPappas CapitalHengdian Group CapitalThe Leukemia & Lymphoma Society Therapy Acceleration Program
Beyond the preview
Go deeper on Solu Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solu Therapeutics.